Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

by | May 15, 2025 | Clinical Trials | 0 comments

​ Conditions: Platinum Resistant Ovarian Cancer

Interventions: Drug: Utidelone Capsules; Drug: Fruquintinib Capsules

Sponsors: Fudan University

Not yet recruiting Conditions: Platinum Resistant Ovarian Cancer
Interventions: Drug: Utidelone Capsules; Drug: Fruquintinib Capsules
Sponsors: Fudan University
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *